Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

E. Gangolli · SciRah

Researcher profile · Semantic Scholar

E. Gangolli

Share profile

E. Gangolli — researcher profile on SciRah

h-index: 10
Works: 28
Citations: 320

Most-cited papers

Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors
J. Goldman, S. Eckhardt, M. Borad, K. Curtis +11 more
2014Clinical Cancer Research47 citations Open access
Semantic Scholar
Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis
April W. Armstrong, M. Gooderham, C. Lynde, C. Maari +12 more
2024JAMA dermatology39 citations Open access
Semantic Scholar
Neurotransmitters activate the human estrogen receptor in a neuroblastoma cell line.
E. Gangolli, O. Conneely, B. O'Malley
1997Journal of Steroid Biochemistry and Molecular Biology38 citations
Semantic Scholar
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
A. Adjei, P. LoRusso, A. Ribas, J. Sosman +8 more
2016Investigational new drugs31 citations Open access
Semantic Scholar
Antitumor Activity of the MEK Inhibitor TAK-733 Against Melanoma Cell Lines and Patient-Derived Tumor Explants
Lindsey N. Micel, J. Tentler, A. Tan, H. Selby +10 more
2014Molecular Cancer Therapeutics26 citations Open access
Semantic Scholar
Abstract C252: A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies.
J. Infante, J. Tabernero, A. Cervantes, S. Jalal +10 more
201325 citations
Semantic Scholar
A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx).
S. Padmanabhan, J. Beck, K. Kelly, N. Munshi +14 more
200922 citations
Semantic Scholar
Reproductive Function in Protein Kinase Inhibitor-Deficient Mice
Mouna Belyamani, E. Gangolli, R. L. Idzerda
2001Molecular and Cellular Biology15 citations Open access
Semantic Scholar
Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial
S. Kim, Su-Jin Lee, Minhwa Park, S. Park +10 more
2019Translational Oncology11 citations Open access
Semantic Scholar
Phase 1 trial of the adenosine A2A receptor antagonist inupadenant (EOS-850): Update on tolerability, and antitumor activity potentially associated with the expression of the A2A receptor within the tumor.
L. Buisseret, S. Rottey, J. de Bono, A. Migeotte +10 more
202110 citations Open access
Semantic Scholar
MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors: Phase I study.
D. Rasco, A. Olszanski, A. Patnaik, G. Espino +7 more
20139 citations
Semantic Scholar
Phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: Clinical update.
M. Noel, Kurt C. Demel, Bhaskar Srivastava, Scott R. Daigle +12 more
2024Journal of Clinical Oncology8 citations Open access
Semantic Scholar
Rucaparib plus enzalutamide in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Pharmacokinetics (PK) and safety data from the phase Ib RAMP study.
Arpit Rao, D. Morris, V. Assikis, G. Jha +6 more
20218 citations
Semantic Scholar
Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.
A. Adjei, P. LoRusso, A. Ribas, J. Sosman +9 more
20137 citations
Semantic Scholar
Clinical pharmacokinetics (PK) and translational PK-pharmacodynamic (PD) modeling and simulation to predict antitumor response of various dosing schedules to guide the selection of a recommended phase II dose (RP2D) and schedule for the investigational agent MLN0128.
C. Patel, Mayank Patel, A. Chakravarty, E. Gangolli +10 more
20135 citations
Semantic Scholar
Abstract 445: Genomic characteristics and response to rucaparib and enzalutamide in the phase 1b RAMP study of metastatic castration-resistant prostate cancer (mCRPC) patients
Arpit Rao, C. Ryan, D. Morris, V. Assikis +6 more
2021Clinical research4 citations
Semantic Scholar
751 Monotherapy results from an ongoing phase 1a dose escalation study of NDI-101150, a highly selective oral hematopoietic progenitor kinase 1 (HPK1) inhibitor
D. Sommerhalder, M. Noel, S. Boiko, Scott R. Daigle +10 more
2023Regular and Young Investigator Award Abstracts3 citations Open access
Semantic Scholar
Abstract 3738: A rationale for combining the targeted investigational agents TAK-733, a MEK1/2 inhibitor, with alisertib (MLN8237), an Aurora A kinase inhibitor, for cancer therapy
Sabrina C. Collins, D. Blair, Jodi L. Zarycki, C. Szynal +4 more
20123 citations
Semantic Scholar
Multicenter, Dose-Escalation Study of the Investigational Drug Tak-733, An Oral Mek inhibitor, in Patients (PTS) with Advanced Solid Tumors: Preliminary Phase 1 Results
A. Adjei, P. LoRusso, A. Ribas, J. Sosman +6 more
20123 citations Open access
Semantic Scholar
Abstract B189: MLN0128, an investigational mTORC1/2 inhibitor, demonstrates potent antitumor activity alone and in combination with paclitaxel in preclinical models of endometrial cancer.
K. Kannan, Robyn Fabrey, J. Cooper, J. Huck +3 more
20132 citations
Semantic Scholar
Abstract 3739: TAK-733, an investigational, selective MEK1/2 inhibitor, in combination with alisertib (MLN8237), an investigational, selective Aurora A kinase inhibitor is tolerated and results in additive to synergistic antitumor activity: Results from In Vivo Studies
Robyn Fabrey, Shawn M. O’Connell, A. Stanton, A. Chakravarty +4 more
20122 citations
Semantic Scholar
Expression of matrix metalloproteinase 1 (MMP1) and dickkopf-1 (DKK1) in bone metastatic tissue (BMT) and in serum of patients with bone metastases (BM) from different solid tumors
L. Costa, I. Luis, I. Alho, A. Fernandes +6 more
20112 citations
Semantic Scholar
1340 NDI-101150 is a potent and highly selective hematopoietic progenitor kinase 1 (HPK1) inhibitor that promotes a robust and broad anti-tumor immune response
David N. Ciccone, Fu-Shan Kuo, S. Boiko, Scott R. Daigle +8 more
2023Regular and Young Investigator Award Abstracts0 citations Open access
Semantic Scholar
Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors
J. Goldman, S. Eckhardt, M. Borad, K. Curtis +11 more
20150 citations
Semantic Scholar
Abstract A41: Automated immunohistochemistry of phosphobiomarkers: Case study of MTOR (MLN0128) and PI3Kα (MLN1117) investigational inhibitors, single agent and in combination, on xenografts and mouse skin
Anna C. Kreshock, I. Natalia, Yueying Cao, Jeff Szwaya +9 more
20150 citations
Semantic Scholar
Abstract B28: Identification of drug-response biomarkers for combined mTORC1/2 and MEK1/2 investigational agents using a large-scale cancer cell line screen.
Hyunjin Shin, D. Blair, Bin Li, G. Hather +3 more
20130 citations
Semantic Scholar
Abstract 3532: Preclinical-to-clinical translation of optimal schedule for MLN0128, an investigational novel small-molecule selective mTOR1/2 inhibitor, based on exposure-efficacy modeling.
Mayankbhai Patel, J. Staunton, J. Mettetal, S. Palani +9 more
20130 citations
Semantic Scholar
Deﬁcient Gene Expression in Protein Kinase Inhibitor a Null Mutant Mice
E. Gangolli, Mouna Belyamani, Sara Muchinsky, A. Narula +4 more
20000 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Bhaskar Srivastava×4
Invite
Bhaskar Srivastava — researcher profile on SciRah
R. Neuwirth×4
Invite
R. Neuwirth — researcher profile on SciRah
V. Bozon×4
Invite
V. Bozon — researcher profile on SciRah
E. Westin×4
Invite
E. Westin — researcher profile on SciRah

×4

Invite

A. Chakravarty — researcher profile on SciRah

Invite

P. LoRusso — researcher profile on SciRah

Invite

A. Ribas — researcher profile on SciRah

Invite

J. Sosman — researcher profile on SciRah

Invite

G. Dy — researcher profile on SciRah

Xiao-Fei Zhou×3

Invite

Xiao-Fei Zhou — researcher profile on SciRah

Invite

M. Kneissl — researcher profile on SciRah

Invite

S. Faucette — researcher profile on SciRah